Genmab A (GMAB) Total Debt (2019 - 2026)
Genmab A (GMAB) reported Total Debt of $4.9 billion for Q1 2026, up 3349.65% on a YoY basis from $143.0 million in Q1 2025, and down 6.47% quarter-over-quarter from $5.3 billion in Q4 2025.
Genmab A (GMAB) Total Debt (2019 - 2026) Analysis & Trends
Genmab A has reported Total Debt for 4 years, with the latest figure at $4.9 billion in Q1 2026.
- For the quarter ending Q1 2026, Total Debt rose 3349.65% year-over-year to $4.9 billion; the trailing twelve-month figure through Mar 2026 stood at $4.9 billion (up 3349.65% YoY), and the FY2025 full-year result was $5.3 billion, changed N/A from the prior year.
- Total Debt for Q1 2026 stood at $4.9 billion, down from $5.3 billion in the prior quarter.
- The five-year high for Total Debt was $5.3 billion in Q4 2025, with the low at $143.0 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 319.10 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | Genmab A | 48.34 Bn | 46.82 Bn | 831.00 Mn | 4.93 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.93 Bn |
| Dec 31, 2025 | 5.27 Bn |
| Mar 31, 2025 | 143.00 Mn |
| Sep 30, 2020 | 337.00 Mn |
| Dec 31, 2019 | 181.00 Mn |
| Sep 30, 2019 | 188.61 Mn |